As of May 17, 2023, Disc Medicine Opco’s shares opened at $33.39 on the NASDAQ stock exchange. The company, which specializes in discovering and developing novel treatments for patients with hematologic diseases, has seen a one-year low of $11.80 and a one-year high of $35.03. Its fifty-day moving average price stands at $25.98.
Various research reports have been conducted on the company by different firms, such as Stifel Nicolaus, Lifesci Capital, Morgan Stanley, Raymond James, and SVB Securities. A consensus of their ratings is that the stock is a “buy” with a consensus target price of $37.29.
Looking at Disc Medicine Opco’s quarterly earnings results last May 15th, the company had reportedly missed analysts’ consensus estimates by posting ($1.20) earnings per share for the quarter instead of ($0.67).
Disc Medicine Opco has significant potential due to its portfolio of therapeutic candidates targeting fundamental biological pathways of heme biosynthesis and iron homeostasis that underlie red blood cell biology for serious hematologic diseases treatment. As an innovative clinical-stage biotechnology firm with various buy recommendations from analysts’ reports, this company may remain an enticing investment opportunity until their next earnings report unveils new insights into its operations and financials moving forward towards greater heights within this sector’s field.
[bs_forecast_slider ticker=”IRON”]
Disc Medicine Opco Inc (NASDAQ:IRON) Sees Increase in Q2 EPS Estimates and Changes in Investor Positions
Disc Medicine Opco Inc (NASDAQ:IRON) has seen an increase in Q2 2023 EPS estimates, according to a report by SVB Leerink released on May 15th. The report states that T. Smith, an analyst at the company, now predicts that Disc Medicine Opco will earn ($0.65) per share for the quarter, up from their previous prediction of ($0.68). SVB Leerink holds an “Outperform” rating and a $36.00 price target on the stock.
However, it should be noted that large investors have recently made changes to their positions in the stock. Bank of America Corp DE increased its holdings by 134,000.0% during the first quarter, now owning 2,682 shares valued at $57,000 after acquiring an additional 2,680 shares in the last quarter.
Similarly, Citigroup Inc. purchased a new position in Disc Medicine Opco during the fourth quarter valued at about $101,000; Barclays PLC’s holdings increased by 2,709.5% during the first quarter and now owns 5,619 shares valued at $119,000 after acquiring an additional 5,419 shares in the last quarter.
UBS Group AG also purchased a new position during the fourth quarter valued at about $142,000 while Boxer Capital LLC bought an investment worth roughly $176k during this time too. It is important to highlight that hedge funds and other institutional investors own 75.42% of all stocks within this company.
Despite these changes to investor portfolios and predictions about earnings for FYs up until FY2027 that range from ($2.90) to ($9.67) per share depending on which year we’re looking at respectively; Disc Medicine Opco remains optimistic concerning their future revenue growth potential.
Their newest therapies targeting rare diseases with unmet needs using proprietary platform technologies like KARISMA and Endure show promise for revolutionizing the medical sector.
Overall, investors remain hopeful for a positive outlook of Disc Medicine Opco’s economic position in the near future.
